Image Place holder

Hye Sook Chon, MD

Specialty: Gynecologic Oncology
Program: Gynecologic Oncology

Call 1-888-MOFFITT

or call 1-888-MOFFITT


Dr. Chon is a gynecologic oncologist in the Center for Women’s Oncology at Moffitt. She provides medical and surgical care to women with gynecologic malignancies and pre-invasive disease of the lower genital tract. Dr. Chon has completed her residency training in Obstetrics and Gynecology at Kyung Hee Univeristy, Seoul, Korea and Baylor College of Medicine, Houston, TX and fellowship in Gynecologic Oncology at Moffiitt Cancer Center/University of South Florida. Dr. Chon has a special interest in minimally invasive surgery, including robotic-assisted laparoscopy, for appropriate patients with gynecologic malignancies.  Minimally invasive surgery has revolutionized care for patients with gynecologic malignancies while improving patients’ quality of life postoperatively. In addition to providing excellent patient care, Dr. Chon continues to pursue her research interests which include surgical innovation and outcomes in gynecologic malignancies, and personalizing treatment options for patients with endometrial cancer.  Dr. Chon believes in working closely with the patient and the referring doctor in order to provide quality care through a comprehensive, multidisciplinary approach.

Education & Training

Board Certification:

  • Gynecologic Oncology


  • MD Anderson International Fellow - Gynecologic Medical Oncology
  • H. Lee Moffitt Cancer Center & Research - Gynecologic Oncology


  • Kyung Hee University Medical Center - Obstetrics and Gynecology
  • Baylor College of Medicine - Obstetrics and Gynecology

Medical School:

  • Kyung Hee University College of Medicine - MD
Participating Trials

Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence)
Condition: Gynecological Tumor
Intervention: ADXS11-001; Placebo

Phase 1-2 Study Of Medi4736 Alone or in Combination With Adxs11-001 In Recurrent/Persistent or Metastatic Cervical or HPV + Head & Neck Cancer
Condition: Gynecological Tumor
Intervention: ADXS11-001; MEDI4736 (Durvalumab)

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Condition: Gynecological Tumor
Intervention: Triapine; cisplatin

Sickness Behaviors in Gynecologic Cancer Patients Treated with Chemotherapy
Condition: Gynecological Tumor

A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Condition: Gynecological Tumor
Intervention: Caelyx; Doxil (doxorubicin liposome); Yondelis (Trabectedin)

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Peglyated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
Condition: Gynecological Tumor
Intervention: Doxil (doxorubicin liposome); Farletuzumab; Paraplatin (carboplatin); Placebo; Taxol (paclitaxel); carboplatin; doxorubicin liposome; paclitaxel

A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
Condition: Genitourinary
Intervention: MK-3475 (Keytruda); Ziv-aflibercept

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology.
Condition: Gynecological Tumor
Intervention: Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128 + MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
Condition: Gynecological Tumor
Intervention: MLN0128; MLN1117; TAK-228 (MLN0128); Taxol (paclitaxel); paclitaxel

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Condition: Multiple
Intervention: Not Applicable; Pembrolizumab (Keytruda)

A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
Condition: Gynecological Tumor
Intervention: Fluconazole; IL-2 (Interleukin-2); LN-145; MESNA; Neupogen (filgrastim); cyclophosphamide; cytoxan (cyclophosphamide); filgrastim; fludarabine (Fludarabine phosphate)

A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
Condition: Gastrointestinal Tumor
Intervention: MGD007

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


  • Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham RM. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC Cancer. 2017 Jun;17(1):407. Pubmedid: 28595616. Pmcid: PMC5465458.
  • Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Valea FA, Wyse E, Yashar CM, McMillian N, Scavone J. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Jan;15(1):92-120. Pubmedid: 28040721.
  • Han HS, Magliocco AM. Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer. Clin Breast Cancer. 2016 Jun;16(3):166-179. Pubmedid: 27103546.
  • Abdallah R, Chon HS, Bou Zgheib N, Marchion DC, Wenham RM, Lancaster JM, Gonzalez-Bosquet J. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data. Int J Gynecol Cancer. 2015 Jul;25(6):1000-1009. Pubmedid: 26098088.
  • Abdallah R, Chon HS, Gonzalez Bosquet J. Gene expression and prediction of complete cytoreduction in ovarian cancer. Obstet Gynecol. 2014 May;123 Suppl 1:89S. Pubmedid: 24770297.
  • Chon HS, Abdallah R, Bosquet JG. Association between endometrial cancer risk classification and gene expression in the cancer genome atlas database. Obstet Gynecol. 2014 May;123 Suppl 1:90S. Pubmedid: 24770301.
  • Gonzalez Bosquet J, Marchion DC, Chon H, Lancaster JM, Chanock S. Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data. Cancer Res. 2014 Jul;74(14):3902-3912. Pubmedid: 24848511.
  • Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM. Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep. 2014 Jan;31(1):376-383. Pubmedid: 24220856. Pmcid: PMC3981115.
  • Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Zgheib NB, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Gynecol Oncol. 2013 Oct;131(1):207-212. Pubmedid: 23877012.
  • Marchion DC, Xiong Y, Chon HS, Sawah EA, Zgheib NB, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM. Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Am J Obstet Gynecol. 2013 Dec;209(6):576.e1-576.e16. Pubmedid: 23933223. Pmcid: PMC3840156.
  • Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Brit J Cancer. 2012 Jun;106(12):1967-1975. Pubmedid: 22596241. Pmcid: PMC3388569.
  • Zgheib NB, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol. 2012 Jul;41(1):179-188. Pubmedid: 22552627. Pmcid: PMC4017641.
  • Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Zgheib NB, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul;22(6):960-967. Pubmedid: 22740002. Pmcid: PMC4036555.
  • Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Zgheib NB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012 Jan;124(1):119-124. Pubmedid: 22032837.
  • Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct;17(19):6356-6366. Pubmedid: 21849418. Pmcid: PMC3186862.
  • Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control. 2011 Jan;18(1):8-15. Pubmedid: 21273975.
  • Ramirez I, Chon HS, Apte SM. The role of surgery in the management of epithelial ovarian cancer. Cancer Control. 2011 Jan;18(1):22-30. Pubmedid: 21273977.
  • Tao X, Chon HS, Fu S, Kavanagh JJ, Hu W. Update on aurora kinase inhibitors in gynecologic malignancies. Recent Pat Anticancer Drug Discov. 2008 Nov;3(3):162-177. Pubmedid: 18991785. Pmcid: PMC3039426.
  • Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets. 2006 Jun;6(4):333-363. Pubmedid: 16848724.
  • Chon HS, Chung HS, Hahn KS, Lee HJ. A case of endometrial squamous cell carcinoma. Korean J Obstet Gynecol. 2003 Apr;46(4):864-868.
  • Chon HS, Lee SK, Kim SB. The accuracy of colposcopic impression among patients undergoing directed biopsy. Korean J Gynecol Oncol Colposc. 2002 Jun;13(2):116-123.
  • Chon HS, Lee SK. A case report of primary peritoneal cancer. Korean J Gynecol Oncol Colposc. 2001 Jun;12(2):156-161.
  • Chung MH, Chon HS, Huh JY. Clinical evaluation on 256 cases of CISH and comparison with TAH. Korean J Gynecol Endoscopy. 2001;13(2):104-114.
  • Chon HS. A case of neoadjuvant chemotherapy with taxol/carboplatin in advanced epithelial ovarian cancer. Korean J Obstet Gynecol. 2000 Oct;43(10):1574-1878.
  • Lee BY, Chon HS, Kim SB. Pelviscopic ovarian drilling in infertile patients in polycystic ovarian syndrome resistant to Clomiphene citrate. Korean J Obstet Gynecol. 2000;43(11):2033-2037.